Phase II trial of adjuvant chemotherapy with modified medication of S-1 for pancreatic cancer

Phase II trial of adjuvant chemotherapy with modified medication of S-1 for pancreatic cancer - Phase II trial of adjuvant chemotherapy with S-1 for pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002791

Enrollment

Registered

2009-12-01

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

S1 80mg/sq day1-14, q1w X 8 courses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically proven pancreatic adenocarcinoma 2)Gross complete resection (R0 or R1) 3)No prior chemotherapy or radiotherapy within 3 years 4)Age above 20 years 5)status of 0 or 1 6)Adequate hematologic, hepatic and renal function 7)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Watery diarrhea 2)Severe mental disorder 3)Active infection 4)Severe complications, such as ileus, heart failure and renal failure 5)Symptomatic pulmonary fibrosis or interstitial pneumonia 6)History of severe anaphylaxies 7)Marked pleural or peritoneal effusion 8)Active concomitant malignancy 9)Treatment with phenytoin, potassium warfarin or flucytosine

Design outcomes

Primary

Measure	Time frame
disease free survival	—

Secondary

Measure	Time frame
adverse events, overall survival and compliance	—

Countries

Japan

Contacts

Public ContactMasayuki Koizumi

Kyoto University Hospital Division of HBP surgery and Transplantation

tmasui@kuhp.kyoto-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026